Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D® Clinical & Research Congress 2026 highlighting CNTY-813 Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion™ 5.0 into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and investments of $197.2 million as of June 30, 2026 PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including T1D, and cancer, today reported financial results for the second quarter ended June 30, 2026, and recent business highlights. "We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale," said Brent Pfeiffenberger, Pharm.D.
